Cite
HARVARD Citation
Evrard, C. et al. (2021). PRODIGE 59-DURIGAST trial: A randomised phase II study evaluating FOLFIRI + Durvalumab ± Tremelimumab in second-line of patients with advanced gastric cancer. Digestive and liver disease. 53 (4), pp. 420-426. [Online].